Aurinia Pharmaceuticals (AUPH) Receives Daily News Sentiment Score of 0.19
News headlines about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 44.9408297549363 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s analysis:
- Investors may need a consensus Analysts Rating: Aurinia Pharmaceuticals Inc. (AUPH) – Wall Street Morning (wallstreetmorning.com)
- Investors may need a consensus Analysts Rating: Aurinia … – Wall Street Morning (wallstreetmorning.com)
- Aurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Attention Seeking Stock – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) – The Investor Guide (wallstreetnews24.com)
- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) – Here’s What to Focus on – Nasdaq Journal (press release) (nasdaqjournal.com)
Several research analysts recently issued reports on the stock. Seaport Global Securities reissued a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, October 6th. Vetr raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $7.35 target price on the stock in a research note on Tuesday, September 19th. Leerink Swann increased their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Cantor Fitzgerald reissued a “buy” rating and set a $14.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. Finally, Canaccord Genuity set a $11.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 24th. Two analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $10.79.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. The business’s revenue for the quarter was up .0% compared to the same quarter last year. equities research analysts forecast that Aurinia Pharmaceuticals will post -1.05 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Aurinia Pharmaceuticals (AUPH) Receives Daily News Sentiment Score of 0.19” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/aurinia-pharmaceuticals-auph-receives-daily-news-sentiment-score-of-0-19/1805410.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.